Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation ...

ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials.

In the rapidly evolving landscape of the clinical trials industry, the integration of robust marketing and sales intelligence solutions has become increasingly important. As stakeholders seek to ...

The company’s VP of digital excellence explains how the Japanese biotech engages with data and uses it to inform decision ...

Endeavor has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial of ENV-101 (taladegib) for IPF.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

Melt Pharmaceuticals has reported results from its Phase III trial of MELT-300 non-opioid sedation tablet for cataract ...

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of ...